(The FASEB Journal. 1999;13:2225-2234.)
© 1999 FASEB
Mitotic signaling by ß-amyloid causes neuronal death
A. COPANI*,
F. CONDORELLI
,
A. CARUSO*,
C. VANCHERI
,
A. SALA§,
A. M. GIUFFRIDA STELLA*,
P. L. CANONICO¶,
F. NICOLETTI
,#1 and
M. A. SORTINO
* Biochemistry and
Pharmacology, School of Medicine, University of Catania, 95125 Catania;
Institute of Respiratory Disease, Ospedale Tomaselli, 95125 Catania, Italy;
§ Consorzio Mario Negri Sud, 66030 S. Maria Imbaro, Chieti, Italy;
¶ Department Internal Medicine and Medical Therapy, University of Pavia, 27100 Pavia, Italy;

Department of Pharmaceutical Sciences, School of Pharmacy, University of Catania, 95125 Catania;
# I. N. M. Neuromed, Localita Camerelle, 86077 Pozzilli, Isernia, Italy
1Correspondence: Department of Pharmaceutical Sciences, Section of Pharmacology, School of Pharmacy, University of Catania, Viale A. Doria 6, 95125 Catania, Italy. E-mail: nicoletti.ferdinando{at}ctonline.it
 |
ABSTRACT
|
|---|
Aggregates of ß-amyloid peptide (ßAP), the main constituent of
amyloid plaques in Alzheimers brain, kill neurons by a not yet
defined mechanism, leading to apoptotic death. Here, we report that
both full-length ßAP(140) or (142) and
its active fragment ßAP(2535) act as proliferative
signals for differentiated cortical neurons, driving them into the cell
cycle. The cycle followed some of the steps observed in proliferating
cells, including induction of cyclin D1, phosphorylation of
retinoblastoma, and induction of cyclin E and A, but did not progress
beyond S phase. Inactivation of cyclin-dependent protein kinase-4 or -2
prevented both the entry into S phase and the development of apoptosis
in ßAP(2535)-treated neurons. We conclude that neurons
must cross the G1/S transition before succumbing to ßAP signaling,
and therefore multiple steps within this pathway may be targets for
neuroprotective agents.Copani, A., Condorelli, F., Caruso, A.,
Vancheri, C., Sala, A., Giuffrida Stella, A. M., Canonico, P. L., Nicoletti, F., Sortino, M. A. Mitotic signaling by ß-amyloid
causes neuronal death.
Key Words: neuronal apoptosis cell cycle Alzheimers disease.
 |
INTRODUCTION
|
|---|
ALZHEIMER’S DISEASE (AD) brain is characterized by
the presence of amyloid plaques, neurofibrillary tangles, and extensive
neuronal loss (1)
. Degenerating neurons show the
morphological features of apoptosis (2
, 3)
. ß-Amyloid
peptide (ßAP), the main constituent of amyloid plaques
(4)
, is believed to play a causative role in the
pathogenesis of AD and induces neuronal apoptosis in vitro
(5
, 6)
. Understanding the mechanism(s) responsible for
ßAP-induced apoptosis may therefore be relevant for the
identification of novel therapeutic strategies in AD. Although numerous
mechanisms have been implicated as initial triggers of ßAP toxicity,
such as activation of surface receptors (7
8
9
10
11)
,
generation of radical oxygen species (12)
, or interference
with cell adhesion to the extracellular matrix (13
, 14)
,
the linking bridge between these initial events and the execution of
apoptosis are still obscure.
We proceeded from the observation that ßAP is toxic to neurons
(5
, 6)
, but does not affect glial cell viability
(15
16
17)
. An induction of c-jun and c-fos has been
causally linked to neuronal apoptosis induced by ßAP (18
, 19)
, and this is supported by the presence of Jun or Fos
immunoreactivity in tangle-bearing neurons of AD brain
(20)
. However, ßAP also induces c-jun and c-fos
expression in astrocytes (21
, 22)
, which are resistant to
death. Knowing that c-jun and c-fos respond to mitotic stimuli in
proliferating cells (23
, 24)
, we have hypothesized that
ßAP generates a proliferative signal, which can be afforded by
astrocytes but may not be tolerated by postmitotic cells such as
neurons.
 |
MATERIALS AND METHODS
|
|---|
Astrocyte culture
Primary cultures of rat cortical astrocytes were prepared from
1-day-old Sprague-Dawley rats. Briefly, cortices were dissected in a
Ca2+/Mg2+ free buffer;
after trituration, suspended cells were plated on 250 ml flasks in
Dulbeccos modified Eagle minimal essential medium (DMEM, Life
Technologies, Inc.) containing 2 mM glutamine, 10% fetal calf serum,
and a penicillin/streptomycin combination (100 units/ml and 100
µg/ml, respectively). Astrocytes were allowed to reach confluency,
then flasks were shaken overnight to eliminate the contaminating
microglia and oligodendrocytes. Astrocytes were harvested by a 0.25%
trypsin-EDTA solution and plated on 35 mm Nunc dishes at a density of
500,000 cells/dish. Before reaching confluency, astrocytes were shifted
in a serum-free DMEM containing 2 mM glutamine, 100 µM putrescine, 20
nM progesterone, and 30 nM selenium 48 h prior to the addition of
ßAP.
Pure neuronal culture
Cultures of pure cortical neurons were obtained from E 15 rat
embryos. Cortices were dissected in a
Ca2+/Mg2+ free buffer;
pieces were collected by slow speed centrifugation and cells were
mechanically dissociated in a plating medium consisting of DMEM/Hams
F12 (1:1) supplemented with the following components: 10 mg/ml bovine
serum albumin, 10 µg/ml insulin, 100 µg/ml transferrin, 100 µM
putrescine, 20 nM progesterone, 30 nM selenium, 2 mM glutamine, 6 mg/ml
glucose, 50 units/ml penicillin, and 50 µg/ml streptomycin. Cortical
cells were plated at a density of 2 x
106/dish on 35 mm Nunc dishes precoated with 0.1
mg/ml poly-D-lysine. Cytosine-ß-D-arabinofuranoside (10 µM) was
added to the cultures 18 h after plating to avoid the
proliferation of non-neuronal elements and was kept for 3 days before
medium replacement. Subsequent partial medium replacements were carried
out every 2 days. This method yields more than 99% pure neuronal
cultures, as judged by immunocytochemistry for glial fibrillary acidic
protein (GFAP) and neuron-specific microtubule-associated protein 2
(MAP-2). ßAP has always been applied to cultures at 812 days
in vitro.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde for 15 min at room
temperature and permeabilized with 0.1% Triton X-100 for 5 min. After
blocking for 30 min with 3% normal goat serum, incubation with
polyclonal GFAP antibodies (Sigma Immunochemicals, 1:100 dilution) was
carried out for 2 h at room temperature. After washing,
biotin-conjugated anti-rabbit secondary antibodies (7 µg/ml) were
added for 1 h. After a 45 min incubation with the ABC complex
(Vectastain ABC-Elite kit, Vector, Burlinghame, Calif.), staining was
developed by
DAB-nickel/H2O2 reaction.
Ten microscopic fields per culture were marked on the dish and
visualized on a video monitor connected to a digital video camera.
Images of the fields were examined for GFAP staining and were
computer-stored prior to MAP-2 staining. For MAP-2 staining, cultures
were blocked for 30 min with 3% horse serum and incubated for 2 h
at room temperature with monoclonal MAP-2 antibodies (Affiniti
Research, 1:1000 dilution). After washing, biotin-conjugated anti-mouse
secondary antibodies (7 µg/ml) were added for 1 h. After a 45
min incubation with the ABC complex, staining was developed by
DAB-/H2O2 reaction. Marked
fields were analyzed for MAP-2 staining and their images were compared
to those previously stored.
Handling of ßA peptides
ßAP(142),
ßAP(140),
ßAP(2535), and the control peptide reverse
ßAP(3525) were purchased from Bachem
Feinchemikalien AG (Bubendorf, Switzerland). Different lots of the
peptides were used. Peptides were solubilized in sterile, doubly
distilled water at an initial concentration of 2.5 mM and stored frozen
at -20°C. Before the experiment, ßAP(142)
and ßAP(140) stock solutions were kept for 1
wk in a 37°C incubator so as to allow aggregation and therefore
toxicity. ßAP(2535) was toxic soon after
solubilization (25)
. The reverse ßAP
(3525) was generally not toxic; however, we
observed some toxicity when it was stored frozen for long periods of
time. All peptides were used to a final concentration of 25 µM in the
presence of the glutamate receptor antagonists MK-801 (10 µM) and
DNQX (30 µM) to avoid the potentiation of endogenous glutamate
toxicity (26)
. ßAP(142) and
ßAP(140) behaved similarly to
ßAP(2535) in activating cell cycle. For this
reason, most of the characterization has been performed with
ßAP(2535), which more reproducibly forms
aggregates in culture.
FACS analysis
For FACS analysis cells were harvested by incubation with
0.25% trypsin for 3 min, and after addition of 50% fetal calf serum
the suspension was centrifuged at low speed. Each pellet was washed
with phosphate-buffered saline and finally fixed in 70% ethanol. Prior
to propidium iodide staining (50 µg/ml in the dark for 30 min),
suspended cells were treated for 1 h at 37°C with RNase (100
µg/ml). DNA content and ploidy were assessed by using a Coulter Elite
flow cytometer. The Multicycle AV software program (Phoenix Flow
Systems, San Diego, Calif.) was used to analyze cell cycle distribution
profiles.
For immunofluorescent staining, suspended cells, prepared as described
above, were permeabilized with 0.01% triton-X100 and then stained for
1 h at 4°C with a mouse monoclonal antibody to MAP-2 (Affiniti
Research Products, 1:750 dilution) or with a rabbit polyclonal phospho-
retinoblastoma (RB) antibody (Medical & Biological Laboratories Co.,
Ltd., Tokyo, Japan; 1 µg/ml) specific for a phospho-Ser containing
peptide (one-letter code: TRPPTLS(p)PIPHIP-KLH) conserved in rat,
mouse, and human RB. After washing, FITC-conjugated secondary
antibodies (1:50 dilution) were added for 30 min.
Thymidine incorporation
For measurement of thymidine incorporation, neuronal cultures
were labeled for 20 h with 1 µCi of
[3H]methyl-thymidine (sp. act.: 25 Ci/mmol,
Amersham, Italia). ßAP(2535) was either
co-added or applied 8 and 16 h before ending the incubation. At
the end of the incubation, cultures were washed extensively with
ice-cold phosphate-buffered saline and incubated for 30 min in 1 N
ice-cold HClO4. After two additional washings
with 0.5 N HClO4 and a final wash with ethanol,
precipitates were solubilized with 0.5 N NaOH and aliquots were
collected for measurement of
[3H]methyl-thymidine incorporation.
Bromodeoxyuridine incorporation assay
To assess bromodeoxyuridine (BrdU) incorporation, 10 µM BrdU
(Sigma, St. Louis, Mo.) was added to neuronal cultures together with 25
µM ßAP(2535) and cells were incubated for
18 h. Cells were then fixed for 10 min at -20°C in 95%
ethanol/5% acetic acid. DNA was denatured by incubation with 2 N HCl
for 30 min at room temperature; afterward, cultures were washed twice
(5 min each) with Sorensons buffer 0.4 M for neutralization of HCl.
For double-labeling experiments with anti-MAP-2 and anti-BrdU
antibodies, cultures were first processed for anti-MAP-2 labeling to
demonstrate that the immunostaining with anti-MAP-2 was not affected by
the cell fixation and DNA denaturation procedure used for BrdU
staining. For MAP-2 staining, cultures were blocked for 30 min with 3%
horse serum, then incubated for 2 h at room temperature with
monoclonal MAP-2 antibodies (Affiniti Research, 1:750 dilution). After
washing, Cy3-conjugated anti-mouse secondary antibodies (Vector, 1:200)
were incubated for 45 min. Cells were observed in an inverted
fluorescence microscope with a rhodamine filter. Images of marked
fields stained for MAP-2 were computer-stored before processing for
anti-BrdU labeling. Cultures were blocked again for 30 min with 3%
bovine serum albumin before the addition of monoclonal anti-BrdU
antibodies (Sigma Immunochemicals, 1:1000 dilution) for 1 h. After
washing, Cy3-conjugated anti-mouse secondary antibodies (Vector, 1:200)
were incubated for 45 min and anti-BrdU immunofluorescence was revealed
as described above. Marked fields were analyzed for nuclear BrdU
staining and their images were compared to those previously stored.
Fluorescent secondary antibodies, in the absence of BrdU primary
antibodies, never labeled the nuclear region of MAP-2 stained neurons.
Immunoblotting
For Western blot analysis, neurons were harvested at 4°C in a
10 mM Tris buffer (pH 7.4) containing 5 mM EDTA, 1 mM PMSF, 25 µg/ml
leupeptin, and 0.5% aprotinin. After 10 min centrifugation at 8000
rpm, an aliquot of the supernatants was processed for the assessment of
protein concentration by a bicinchoninic acid kit. Samples were diluted
in sodium dodecyl sulfate-bromphenol blue buffer and boiled for 5 min
before loading. Electrophoresis was performed in sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (30 mA/h) using 60 µg of
cell protein per lane. After separation, proteins were transferred onto
a nitrocellulose membrane (Hybond ECL, Amersham Italia) for 45 min
using a transblot semi-dry transfer cell. After blocking, membranes
were incubated with primary antibodies for 2 h at room
temperature, then repeatedly washed and exposed to horseradish
peroxidase-conjugated secondary antibodies for 1 h at room
temperature. Proteins were visualized using the enhancing
chemiluminescence detection system (ECL, Amersham Italia). The
following primary antibodies were used: mouse monoclonal cyclin D1
antibody (Santa Cruz, final dilution: 1 µg/ml); rabbit polyclonal
phospho-RB antibody (Medical & Biological Laboratories; 1 µg/ml);
rabbit polyclonal cyclin E antibody (Santa Cruz, 1 µg/ml); and rabbit
polyclonal cyclin A antibody (Santa Cruz, 1 µg/ml).
Neuronal transfection
Transfection was carried out as follows: 10 µg of plasmid
containing a cyclin D1 antisense or a dominant negative mutant of Cdk2
(both provided by A. Sala and described in Results) was equilibrated
with 20 µl Lipofectin (Life Technologies, Inc.) in 1 ml of
conditioned medium for 1 h before addition to the culture dish.
Transfection was allowed overnight before fresh medium replacement and
was carried out 36 h before ßAP(2535)
treatment. When necessary, Dex (1 µM) was added 12 h prior to
ßAP(2535) addition. Transfection efficiency
was quantitated by cotransfecting 10 µg of the leukocyte marker CD20
in a pCMV-neo-Bam vector. Cell surface expression of CD20 was revealed
by staining living cells with a PE-conjugated anti CD20 mouse
monoclonal antibody (Immunotech, Marseille, France; 1:10 dilution),
followed by fixation with 2% paraformaldehyde and FACS analysis.
Mock-transfected neurons were used for control of CD20 staining.
Hoechst chromatin staining in transfected cultures
Cultures were stained with the fluorescent chromatin dye,
Hoechst 33258 (0.4 µg/ml for 10 min at 37°C, after 15 min fixation
with 4% paraformaldehyde), after being transfected with either As-D1
or DN-CDK2 and exposed to ßAP(2535) for
24 h. For the identification of neurons transfected with As-D1 (15
µg/dish), cultures were cotransfected with 5 µg/dish of
pEGFP-IRESneo vector encoding for EGFP. Neurons transfected with
DN-CDK2 were instead identified by immunostaining for an influenza
protein HA-epitope tag inserted just prior to the first stop codon of
the DN-CDK2 insert. Immunostaining was performed using an
affinity-purified rabbit polyclonal antibody raised against the
HA-epitope tag (Santa Cruz, 1 µg/ml) and a Cy3-conjugated anti-rabbit
secondary antibody (1:500, Vector Laboratories).
 |
RESULTS
|
|---|
Analysis of cell cycle and apoptotic death in ßAP-treated
cultures
FACS analysis (27)
of pure rat cortical astrocytes
stimulated with ßAP(2535) showed a greater
percentage of cells in S phase (Fig. 1
), which is consistent with an activation of cell cycle.

View larger version (26K):
[in this window]
[in a new window]
|
Figure 1. Cell cycle analysis of rat cortical astrocytes exposed to
ßAP(2535). A) A typical cell cycle
distribution profile in control cultured astrocytes deprived of serum
for 72 h. B) Changes in cell cycle distribution
after exposure to 25 µM of ßAP(2535) (during the last
24 h of serum deprivation). Values are expressed as percent of
astrocytes in G0/G1, S, or G2/M phases of the cell cycle and are the
means ± SE of three determinations, each obtained
from three pooled culture dishes. *P<0.05 (Students
t test), if compared with control. CTRL = control;
ßAP = ßAP(2535).
|
|
To address the same issue in neurons, we first established the
conditions to grow virtually pure cultures of cortical neurons (>99%
MAP-2 positive and GFAP negative; Fig. 2
), which were healthy and viable up to 12 days in vitro
(DIV). Neuronal cultures were treated with
ßAP(142), ßAP(140),
the active fragment ßAP(2535), or the control
reverse ßAP (3525) always in the presence of
a mixture of ionotropic glutamate receptor antagonists. In untreated
cultures or in cultures treated with the reverse ßAP
(3525), <1% of neurons were in S or G2/M
phase (exemplified in Fig. 3A, B
), suggesting that contamination by neuroblasts was
minimal. Addition of 25 µM ßAP(2535) to the
cultures increased substantially the percentage of neurons in S phase,
although no cell was observed in G2/M phase of the cell cycle (Fig. 3C
). ßAP(2535) treatment also
increased the incorporation of
[3H]-methylthymidine into DNA (Fig. 3D
). The neuronal origin of cells synthesizing DNA in
response to ßAP(2535) is also shown by double
fluorescent staining with MAP-2 antibodies and bromodeoxyuridine (Fig. 3E, F
).

View larger version (52K):
[in this window]
[in a new window]
|
Figure 2. MAP-2 immunostaining of cultured cortical neurons. A)
DAB immunostaining with MAP-2 antibodies shows that virtually all
viable cells are MAP-2 positive. In the same microscopic field
(B), no cell is stained with GFAP (bar = 20 µM).
C) Immunofluorescent staining with MAP-2 antibodies was
quantitated by flow cytometry analysis and is expressed as
log10 fluorescence on the x axis.
D) Nonspecific staining by the secondary antibody alone.
In panel C, note that the entire population of cells is
MAP-2 positive. Panel E shows the lack of MAP-2 staining
in cultured astrocytes.
|
|

View larger version (28K):
[in this window]
[in a new window]
|
Figure 3. Activation of the cell cycle induced by ßAP(2535) in
pure cultures of cortical neurons. A) A typical cell
cycle distribution profile of control cultured neurons, where 99.6% of
MAP-2-positive cells falls into the G0/G1 peak; no cells are in the S
phase and only 0.4% of cells are in the G2/M phase. An identical
distribution is observed 16 h after the addition of reverse ßAP
(3525) (B). The cell cycle distribution
profile changed dramatically 16 h after the addition of
ßAP(2535). In panel C, 9.9% of cells
are in S phase (peak under S), whereas the percentage of cells in
G0/G1 phase drops to 90.1%; no cells are found in the G2/M phase.
D) An increase in [3H]methyl-thymidine
incorporation is shown in cultures exposed to ßAP(2535)
for 16 or 20 h. Values are means ± SE of 6
determinations; *P<0.01 (Students t
test). Fluorescent staining for MAP-2 (E) or MAP-2 and
BrdU (F) is shown in a microscopic field from a
culture exposed to ßAP(2535) for 18 h. Arrowheads
point to cells positive for both MAP-2 and BrdU. No cells in control
cultures were immunopositive for BrdU. Bar = 20 µM.
|
|
FACS analysis revealed that in most of the cultures the percentage of
neurons found in S phase increased to ~810% between 8 and 16 h after addition of ßAP(2535), and declined
to 45% at 20 h (Fig. 4A
). In the same cultures,
ßAP(2535)-induced apoptosis (quantitated by
FACS as in Fig. 4C, D
) increased linearly between 8 and
20 h (Fig. 4B
). The same extent of neuronal apoptosis
was detected by Hoechst staining in sister cultures (not shown). A
similar time course for both S phase and apoptosis was observed after
incubating the cultures with ßAP(140) and
ßAP(142) (Fig. 4E, F
). No effects
were induced by ßAP(142) applied to the
cultures immediately after solubilization, i.e., under conditions in
which the peptide does not form toxic aggregates at least during the
first 24 h in culture (see legend of Fig. 4
). These results
therefore suggest that cortical neurons exposed to ßAP undergo
apoptosis after entering S phase. The smaller percentage of neurons in
S phase with respect to the percentage of apoptotic neurons may reflect
a rapid transfer from S phase into the apoptotic phenotype.

View larger version (35K):
[in this window]
[in a new window]
|
Figure 4. The time course of ßAP(2535)-induced S phase and
apoptosis is shown in panels A and B,
respectively. Values are means ± SE of 7 individual
culture dishes. *P<0.01 vs. the respective controls and
#P<0.01 vs. ßAP(2535) values at 16 h (one-way ANOVA + Fisher PLSD test). ßAP =
ßAP(2535). Samples were simultaneously analyzed for
cell cycle and apoptotic degeneration by FACS, where apoptotic cells
appear as an area preceding the G0/G1 DNA peak (areas of hypoploid DNA
under the horizontal bars). C, D) The
extent of apoptotic death in control cultures or in cultures treated
with ßAP(2535) for 16 h. E, F) The
time dependence of both ßAP(140) and
ßAP(142)-induced S phase and apoptosis, respectively.
Values are means ± SE of 34 individual culture
dishes. *P<0.01 vs. the respective controls; #P<0.01 vs. ßAP values
at 16 h (one-way ANOVA + Fisher PLSD test). Values of freshly
solubilized ßAP(142) were S phase neurons = 1 ± 0.2% and apoptotic neurons = 28 ± 3% at 24 h
(n=4).
|
|
Sequential expression of cell cycle proteins in ßAP-treated
neurons
To examine whether neurons exposed to ßAP enter S phase
following the typical sequence of events driving the G0-G1/S
transition, we have measured 1) the induction of cyclin D1
and phosphorylation of RB protein by activated cyclin-dependent protein
kinase 4 (Cdk4) as events associated with mid G1
phase, and 2) the induction of cyclin E and A, as markers of
late G1 and S phase, respectively (28
, 29)
. Western blot
analysis with anti-cyclin D1 antibodies revealed a 34 kDa band
corresponding to the molecular mass of cyclin D1. Expression of cyclin
D1 was low in control cultures and increased in response to
ßAP(2535), showing a peak at 4 h. Cyclin
D1 levels were still detectable at 8 h, but markedly decreased
after 20 h of exposure to ßAP(2535)
(Fig. 5
). The amount of phosphorylated RB (pRB) was also increased by
ßAP(2535) with a similar time course (Fig. 5)
, suggesting an induced formation of functionally active
Cdk4/6-cyclin D1 complex leading to phosphorylation of RB and,
presumably, to the release of the transcription factor E2F
(30)
. Cyclin E, a target of E2F (31)
, and
cyclin A were also induced, but with a longer latency, increasing after
8 h of exposure to ßAP(2535) (Fig. 5)
.
Thus, ßAP-treated neurons enter S phase through the sequential
expression of cell cycle proteins operating in proliferating cells.

View larger version (23K):
[in this window]
[in a new window]
|
Figure 5. Representative immunoblots of cyclin D1, pRB, cyclin E, and cyclin A in
protein extracts from cultures exposed to ßAP(2535) for
420 h. All these immunoblots were obtained from the same culture
preparation. The same blot was stained for cyclin D1 and cyclin E. Two
independent blots were stained for pRB and cyclin A. Equal amounts of
proteins (60 µg) were loaded per lane, as revealed by rouge ponceau
staining (not shown). In the cyclin D1 immunoblot, a second band of
higher molecular mass (46 kDa) was detected (not shown). This band may
correspond to cyclin X, a putative G1 cyclin that is abundantly
expressed in neurons and is known to cross-react with cyclin D1
antibodies (52)
. This protein was constitutively expressed
in our cultures and did not change substantially after
ßAP(2535) treatment. C = control cultures;
ßAP = ßAP(2535).
|
|
Activation of cell cycle in response to ßAP is causally related
to neuronal death
To examine the relationship between activation of cell cycle and
neuronal death, we transfected the cultures with a dexamethasone (Dex)
-inducible cyclin D1 antisense (As-D1) (32)
or a dominant
negative mutant of Cdk2 (DN-CDK2) (29)
. The As-D1 is a 606
bp murine cDNA fragment ligated in an antisense orientation with
respect to the Dex-inducible MMTV-LTR promoter contained in the
pMAM-neo vector (32)
; the DN-CDK2, in which a dominant
negative mutation was introduced by an Asp to Asn mutation at the
protein kinase KLADFGLAR consensus site, was inserted in a pCMV-neo-Bam
vector (29)
. For the control of transfection efficiency,
cultures were cotransfected with a pCMV-neo-Bam vector expressing the
leukocyte marker CD20, which was revealed by immunofluorescent
staining. Cytofluorometric analysis showed that 1830% of neurons
were CD20 immunopositive in different experiments (exemplified in
Fig. 6
). Induction of As-D1 by 1 µM Dex reduced the percentage of neurons
entering S phase (Fig. 7A
) as well as the amount of the direct Cdk4/6-cyclin D1
target, pRB (Fig. 7C, D
), in cultures exposed to
ßAP(2535). Control As-D1 transfection without
Dex (i.e., a condition in which As-D1 cannot be expressed) had no
effect (Fig. 7A
). CMV-mediated expression of DN-CDK2 gave
results comparable to those obtained by As-D1 + Dex (Fig. 7A
). The induced expression of both As-D1 (in the presence
of Dex) and DN-CDK2 significantly protected against
ßAP(2535)-induced apoptosis as assessed by
cytofluorometric analysis (Fig. 7B
). In addition, neurons
expressing As-D1 after treatment with Dex always showed integrity of
nuclear chromatin as revealed by Hoechst 33258 staining in cells
coexpressing the enhanced green fluorescent protein (EGFP) (Fig. 8A, B,G
). In contrast, the majority of EGFP-positive cells from cultures
not treated with Dex (i.e., transfected but not expressing As-D1)
showed signs of chromatin fragmentation and/or condensation (Fig. 8C, D, G
). Hoechst staining also showed integrity of nuclear
chromatin in neurons expressing DN-CDK2, identified by immunostaining
for an influenza hemagglutinin (HA)-epitope tag (Fig. 8E, F, G
). Taken collectively, these results indicate that activation of
cell cycle is not only antecedent to but also causally related to
neuronal death. Because of the unexpectedly high extent of
neuroprotection in transfected cultures, we wondered whether primarily
surviving neurons might have spread the protection to other neurons in
culture through the production of soluble factors. Cultures were
therefore transfected with As-D1 ± Dex and then treated with
ßAP(2535) for 20 h. The medium collected
from ßAP(2535)-treated cultures expressing
As-D1 (i.e., transfected with As-D1 + Dex) was neuroprotective when
applied to receiving cultures, which in turn were treated with
ßAP(2535). Protection was not observed with
the medium collected from cultures untreated with Dex (Table 1
). To further support a causal relationship between cell cycle induction
and neuronal death, we treated the cultures with chemical inhibitors of
the cell cycle such as mimosine (33)
, an inhibitor of
cdks by competing for the ATP binding domain of the kinases,
deferoxamine (34)
, a chelator of the iron required for the
onset of DNA synthesis, or transforming-growth factor ß (TGF-ß),
which induces cell cycle arrest in a number of proliferating cells
(35)
and protects human neurons against ßAP toxicity
(36)
. All these agents substantially reduced the
percentage of neurons in S phase after exposure to
ßAP(2535) and were neuroprotective against
ßAP(2535)-induced apoptosis (Fig. 7E, F
).

View larger version (15K):
[in this window]
[in a new window]
|
Figure 6. Assessment of transfection efficiency in cultured cortical neurons.
A) Cultures cotransfected with the cyclin D1 antisense
plasmid and a pCMV-neo-Bam vector encoding the leukocyte marker, CD20.
Cytofluorometric analysis of CD20 performed 40 h after
transfection shows that >24% of cells are transfected in this
particular example. B) Control CD20 staining in
mock-transfected cells. The efficiency of CD20 expression ranged from
18 to 30% when the antigen was cotransfected with cyclin D1 antisense
or with the dominant negative mutant of Cdk2.
|
|

View larger version (40K):
[in this window]
[in a new window]
|
Figure 7. Cell cycle inhibitors protect against ßAP(2535)-induced
apoptosis. Expression of a cyclin D1 antisense (As-D1) or a dominant
negative mutant of CDK2 (DN-CDK2) reduces the percentage of neurons in
the S phase (A) and the extent of apoptotic degeneration
(B) in cultures exposed for 18 h to
ßAP(2535). This incubation time has been selected to
examine simultaneously ßAP(2535)-induced S phase and
apoptosis. Values are means ± SE of 46
determinations. *P<0.01 (one-way ANOVA + Fisher PLSD
test). Dex = dexamethasone (1 µM); ßAP =
ßAP(2535) . Expression of pRB in As-D1 transfected
cultures 4 h after exposure to ßAP(2535)
(CE). pRB expression of transfected neurons was
quantitated by flow cytometry analysis by using an antibody that reacts
with RB phosphorylated at Ser 780 by CDK4/cyclin D1 (see Materials and
Methods). E) Cultures expressing the As-D1 and exposed
to ßAP(2535) show a shift to the left in the
distribution of immunofluorescence, indicative of a reduced expression
of pRB, as compared with control cultures (C) or with As-D1 transfected
cultures not treated with Dex (D) both exposed to
ßAP(2535). Cultures treated with
ßAP(2535) expressing the DN-CDK2 show an expression of
pRB similar to control cultures treated with ßAP(2535)
(not shown). The effect of mimosine (400 µM), deferoxamine (1 mM), or
TGF-ß2 (5 ng/ml) on the induction of S-phase and apoptosis by an
18 h exposure to ßAP(2535) is shown in panels
E and F, respectively. Values are
expressed as permeants ± SE of 6 determinations.
*P<0.01 (one-way ANOVA + Fisher PLSD test) if compared
with cultures treated with ßAP(2535) alone. ßAP = ßAP(2535).
|
|

View larger version (37K):
[in this window]
[in a new window]
|
Figure 8. Fluorescent chromatin staining in cells expressing a cyclin D1
antisense (As-D1) or a dominant negative mutant of CDK2 (DN-CDK2).
A, C) Examples of ßAP(2535)-treated
neurons transfected with As-D1, as revealed by EGFP expression.
However, in panel A, As-D1 expression was induced in
transfected cells by Dex treatment, whereas cultures in panel
C were not treated with Dex and therefore As-D1 could
not be expressed in transfected cells. The difference in chromatin
staining between the two conditions is shown in panels B
and D, respectively. Transfected apoptotic neurons
showed a more faint EGFP fluorescence than transfected viable neurons
(see the difference between panels A and
C). E, F) Nuclear integrity of neurons transfected with DN-CDK2,
identified as immunopositive for the HA-epitope tag. Arrowheads point
to transfected neurons (A, C, E) and to the
corresponding nuclei (B, D, F). Open arrowheads indicate
examples of apoptotic neurons with condensed chromatin; straight arrows
in panels D andF point to apoptotic
neurons with fragmented chromatin; curved arrows in all panels point to
the less bright and regularly dispersed chromatin typical of viable
neurons. Bar = 10 µM. G) The percentage of viable
and apoptotic neurons in cultures transfected with As-D1 (identified as
immunopositive for EGFP) treated or not with dexamethasone (Dex) (i.e.,
expressing or not expressing As-D1) or in cultures transfected with
DN-CDK2 (identified as immunopositive for the HA tag). In cultures
transfected with As-D1 and exposed to ßAP(2535) 12 h after addition of Dex, 12 ± 4.5% of neurons
(n=3 dishes) were EGFP positive (EGF+). This value
refers to 100%. Note that all EGFP-positive neurons were viable in
cultures treated with Dex. In cultures transfected with As-D1 and
treated with ßAP(2535) but without Dex, 9 ± 3.2%
of neurons (n=3 dishes) were scored as EGFP positive;
note that in this group, the majority of transfected neurons were
scored as apoptotic. In cultures transfected with DN-CDK2 and treated
with ßAP(2535), the percentage of HA+-positive neurons
was 16 ± 3.4 (n=3). All HA+ neurons were viable.
Cultures were always exposed to ßAP(2535) for 24 h. ßAP = ßAP(2535).
|
|
View this table:
[in this window]
[in a new window]
|
Table 1. ßAP(2535)-induced apoptosis in cultured cortical
neurons incubated with conditioned medium collected from cultures
treated with ßAP(2535) after being transfected with
As-D1 (with or without Dex)a
|
|
 |
DISCUSSION
|
|---|
Present data indicate that ßAP behaves as a mitotic stimulus
leading to proliferation or death depending on the status, dividing or
postmitotic, of the cell type. This situation diverges from some
experimental models carrying an intrinsic toxic potential [e.g.,
neurons either deprived of a trophic support (3740) or challenged
with toxic compounds (4143)] in which an association between
reappearance of cell cycle proteins and apoptotic death has been
reported. ßAP-treated neurons not only expressed the typical
repertoire necessary for the G1/S transition, but also began to
duplicate their DNA. This is clearly shown by FACS analysis, which, as
opposed to more conventional methods such as
[3H]methyl-thymidine incorporation or BrdU
staining, provides a quantitative assessment of DNA per single cell.
The peak in S phase was found 16 h after treatment with ßAP,
whereas apoptosis was maximal later on. This suggested that neurons
enter the S phase before undergoing apoptotic death. The lower
percentage of neurons in S phase as compared to apoptotic neurons may
reflect the stochastic nature of apoptosis. Apoptotic neurons can only
be scored at an end point because of their permanent phenotype, whereas
S-phase neurons are scored only in a transient period of time that they
may cross asynchronously before dying. A causal relationship between
activation of cell cycle and neuronal death was suggested by a series
of experiments in which neurons were protected against ßAP toxicity
when treated with chemical inhibitors of the cell cycle or when
transfected with an As-D1 or a DN-CDK2. The extent of protection
exceeded the number of transfected neurons. This may reflect the
release of an unknown protective factor from neurons that generally
survive to ßAP, as shown by experiments in which the conditioned
medium was transferred from transfected cultures into sister cultures
challenged with ßAP. These results agree with the protective effect
of dominant negative forms of Cdk4 or Cdk6 found in sympathetic neurons
deprived of nerve growth factor (NGF) (40)
. Sympathetic
neurons, however, are not affected by a dominant negative form of Cdk2
(40)
, which was instead protective in our model. Thus,
activation of an unscheduled cell cycle may be common to several forms
of neuronal apoptosis, but subtle differences exist with respect to the
cell type and death paradigm. For example, as opposed to NGF-deprived
sympathetic neurons (40)
, cortical neurons challenged with
ßAP must cross the late G1/early S phase (a process that requires
Cdk2 activation) before dying. The mechanism by which ßAP-treated
neurons interrupt the cell cycle and enter the execution phase of
apoptotic death remains to be established. p53 or other potential
targets for Cdk activity may trigger apoptotic death through the
activation of effectors such as caspases, the inhibition of which is
protective against ßAP-induced toxicity (44
, 45)
.
Our finding is in line with recent papers describing the reappearance
of mitotic proteins in neurons from autoptic brain samples of AD
patients (46
47
48
49
50)
. Initially, the reported presence of
mitotic phospho-epitopes in neurons bearing neurofibrillary tangles
(46)
could be interpreted as a terminal byproduct of
apoptotic degeneration; however, more recently, cell cycle markers have
been described in susceptible regions of AD brain, but not necessarily
in late degenerating neurons (50)
. This suggests that the
activation of a cell cycle may be a requisite antecedent to neuronal
death in AD. A relationship between the mitotic cycle and the AD
phenotype has also been inferred from the evidence that presenilin 1
and 2 (which are mutated in most of early-onset familiar AD) are
present in the nuclear membrane and are associated with subcellular
structures involved in cell cycle regulation and mitosis
(51)
.
We now provide evidence that neurons begin a cycle in response to
ßAP: they complete G1, are blocked after entering S phase, and
eventually die. The lack of neurons in G2 phase in our study diverges
from the appearance of cyclin B1 or activated cyclin B1/Cdk1 complex in
AD neurons (49
, 50)
. The absence of specific environmental
factors in our cultures might have prevented progression of the cell
cycle into the G2 phase, as may occur in the AD brain. It is noteworthy
that ßAP-induced neuronal cycle was accompanied by the sequential
expression of cell cycle proteins, because this suggests that targeted
inhibitors of these proteins may function as neuroprotectants in
AD.;1>
 |
FOOTNOTES
|
|---|
Received for publication April 21, 1999. Revised for publication July 26, 1999.
 |
REFERENCES
|
|---|
-
Katzman, R. (1986) Alzheimers disease. N. Engl. J. Med. 314,964-973[Medline]
-
Su, J. H., Anderson, A. J., Cummings, B. J., Cotman, C. W. (1994) Immunoisto-chemical evidence for apoptosis in Alzheimers disease. NeuroReport 5,2529-2533[Medline]
-
Smale, G., Nichols, N. R., Brady, D. R., Finch, C. E., Horton, W. E. (1995) Evidence for apoptotic cell death in Alzheimers disease. Exp. Neurol. 133,225-230[Medline]
-
Masters, C. L., Simms, G., Weinmann, N. A., Multhaup, G., McDonald, B. L., Beyreuther, K. (1985) Amyloid plaque core protein in Alzheimers disease and Downs syndrome. Proc. Natl. Acad. Sci. USA 82,4245-4249[Abstract/Free Full Text]
-
Forloni, G., Chiesa, R., Smiroldo, S., Verga, L., Salmona, M., Tagliavini, F., Angeretti, N. (1993) Apoptosis-mediated neurotoxicity induced by chronic application of ß amyloid fragment 2535. NeuroReport 4,523-526[Medline]
-
Loo, D. T., Copani, A., Pike, C. J., Whittemore, E. R., Walencewicz, A. J., Cotman, C. W. (1993) Apoptosis is induced by ß-amyloid in cultured central nervous system neurons. Proc. Natl. Acad. Sci. USA 90,7951-7955[Abstract/Free Full Text]
-
Boland, K., Manias, K., Perlmutter, D. H. (1995) Specificity in recognition of amyloid-beta peptide by the serpin-enzyme complex receptor in hepatoma cells and neuronal cells. J. Biol. Chem. 270,28022-28028[Abstract/Free Full Text]
-
El Khoury, J., Hickman, S. E., Thomas, C. A., Cao, L., Silverstein, S. C., Loike, J. D. (1996) Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature (London) 382,716-719[Medline]
-
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, M., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., Migheli, A., Nawroth, P., Stern, D., Schmidt, A. M. (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimers disease. Nature (London) 382,685-691[Medline]
-
Narita, M., Holtzman, D. M., Schwartz, A. L., Bu, G. (1997) Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J. Neurochem. 69,1904-1911[Medline]
-
Yaar, M., Zhai, S., Pilch, P. F., Doyle, S. M., Eisenhauer, P. B., Fine, R. E., Gilchrest, B. A. (1997) Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimers disease. J. Clin. Invest. 100,2333-2340[Medline]
-
Hensley, K., Carney, J. M., Mattson, M. P., Aksenova, M., Harris, M., Wu, J. F., Floyd, R. A., Butterfield, D. A. (1994) A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc. Natl. Acad. Sci. USA 91,3270-3274[Abstract/Free Full Text]
-
Zhang, C., Lambert, M. P., Bunch, C., Barber, K., Wade, W. S., Krafft, G. A., Klein, W. L. (1994) Focal adhesion kinase expressed by nerve cell lines shows increased tyrosine phosphorylation in response to Alzheimers A beta peptide. J. Biol. Chem. 269,25247-25250[Abstract/Free Full Text]
-
Sabo, S., Lambert, M. P., Kessey, K., Wade, W., Krafft, G., Klein, W. L. (1995) Interaction of beta-amyloid peptides with integrins in a human nerve cell line. Neurosci. Lett. 184,25-28[Medline]
-
Araujo, D. M., Cotman, C. W. (1992) ß-amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimers disease. Brain Res 569,141-145[Medline]
-
Pike, C. J., Cummings, B. J., Monzavi, R., Cotman, C. W. (1994) ß-amyloid induced changes in cultured astrocytes parallel reactive astrocytosis associated with senile plaques in Alzheimers disease. Neuroscience 63,517-531[Medline]
-
Meda, L., Cassatella, M. A., Szendrei, G. I., Otovos, L., Baron, P., Villalba, M., Ferrari, D., Rossi, F. (1995) Activation of microglial cells by ß-amyloid protein and interferon
. Nature (London) 374,647-650[Medline]
-
Anderson, A. J., Pike, C. J., Cotman, C. W. (1995) Differential induction of immediate early gene proteins in cultured neurons by ß-amyloid (Aß): association of c-jun with Aß-induced apoptosis. J. Neurochem. 65,1487-1498[Medline]
-
Estus, S., Tucker, H. M., van Rooyen, C., Wright, S., Brugham, E. F., Wogulis, M., Rydel, R. E. (1997) Aggregated amyloid-ßprotein induces cortical neuronal apoptosis and concomitant apoptotic pattern of gene induction. J. Neurosci. 17,7736-7745[Abstract/Free Full Text]
-
Anderson, A. J., Cummings, B. J., Cotman, C. W. (1994) Increased immunoreactivity for Jun- and Fos-related proteins in Alzheimers disease: association with pathology. Exp. Neurol. 125,286-295[Medline]
-
Copani, A., Calogero, A., Nicoletti, F. (1996) Induction of immediate early genes by ß-amyloid peptide in cultured glial cells. Soc. Neurosci. Abstr. 22,81.15
-
Ferrer, I., Segui, J., Planas, A. M. (1996) Amyloid deposition is associated with c-Jun expression in Alzheimers disease and amyloid angiopathy. Neuropathol. Appl. Neurobiol. 22,521-526[Medline]
-
Bhat, N. R., Hauser, K. F., Kindy, M. S. (1992) Cell proliferation and proto-oncogene induction in oligodendroglial progenitors. J. Neurosci. 32,340-349
-
Bi, N., Namrack, M. D. (1994) PMA inhibits the growth of human fibroblasts after the induction of immediate-early genes. Exp. Cell Res. 212,105-112[Medline]
-
Pike, C. J., Burdik, D., Walencewicz, A. J., Gable, C. G., Cotman, C. W. (1993) Neurodegeneration induced by ß-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13,1676-1687[Abstract]
-
Copani, A., Bruno, V., Battaglia, G., Leanza, G., Pellitteri, R., Russo, A., Stanzani, S., Nicoletti, F. (1995) Activation of metabotropic glutamate receptor protects cultured neurons against apoptosis induced by ß-amyloid peptide. Mol. Pharmacol. 47,890-897[Abstract]
-
Krishan, A. (1975) Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J. Cell Biol. 66,188-193[Abstract/Free Full Text]
-
Pines, J. (1993) Cyclins and cyclin-dependent kinases: take your partners. Trends Biochem. Sci. 18,195-197[Medline]
-
van De Heuvel, S., Harlow, E. (1993) Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262,2050-2054[Abstract/Free Full Text]
-
Muller, R. (1995) Transcriptional regulation during the mammalian cell cycle. Trends Genet 11,173-178[Medline]
-
Ohtani, K., DeGregori, J., Nevins, J. R. (1995) Regulation of the cyclin E gene by transcription factor E2F1. Proc. Natl. Acad. Sci. USA 92,12146-12150[Abstract/Free Full Text]
-
Sala, A., Calabretta, B. (1992) Regulation of BALB/c 3T3 fibroblast proliferation by B-myb is accompanied by selective activation of cdc2 and cyclin D1 expression. Proc. Natl. Acad. Sci. USA 18,10415-10419
-
Lalande, M. (1990) A reversible arrest point in the late G1 phase of the mammalian cell cycle. Exp. Cell Res. 186,332-339[Medline]
-
Brodie, C., Siriwardana, G., Lucas, J., Schleicher, R., Terada, N., Szepesi, A., Gelfand, E., Seligman, P. (1993) Neuroblastoma sensitivity to growth inhibition by deferoxamine: evidence for a block in G1 phase of the cell cycle. Cancer Res 53,3968-3975[Abstract/Free Full Text]
-
Derynck, R. (1994) TGF-ß receptor-mediated signaling. Trends Biochem. Sci. 19,548-553[Medline]
-
Chao, C. C., Hu, S., Kravitz, F. H., Tsang, M., Anderson, W. R., Peterson, P. K. (1994) Transforming growth factor-beta protects human neurons against ß-amyloid-induced injury. Mol. Chem. Neuropathol. 23,159-178[Medline]
-
Freeman, R. F., Estus, S., Johnson, E. M. (1994) Analysis of cell-related gene expression in postmitotic neurons: selective induction of cyclin D1 during programmed cell death. Neuron 12,343-345[Medline]
-
Gao, C. Y., Zelenka, P. S. (1995) Induction of cyclin B and H1 kinase activity in apoptotic PC12 cells. Exp. Cell Res. 219,612-618[Medline]
-
Farinelli, S. E., Greene, L. A. (1996) Cell cycle blockers mimosine, ciclopirox, and deferoxamine prevent the death of PC12 cells and postmitotic sympathetic neurons after removal of trophic support. J. Neurosci. 16,1150-1162[Abstract/Free Full Text]
-
Park, D. S., Levine, B., Ferrari, G., Greene, L. A. (1997) Cyclin dependent kinase inhibitors and dominant negative cyclin dependent kinase 4 and 6 promote survival of NGF-deprived sympathetic neurons. J. Neurosci. 17,8975-8984[Abstract/Free Full Text]
-
Park, D. S., Morris, E. J., Greene, L. A., Geller, H. M. (1997) G1/S cell cycle blockers and inhibitors of cyclin-dependent kinases suppress camptothecin-induced neuronal apoptosis. J. Neurosci. 17,1256-1270[Abstract/Free Full Text]
-
Shirvan, A., Ziv, I., Machlin, T., Zilkha, Falb, . R.,Melamed, E., Barzilai, A. (1997) Two waves of cyclin B and proliferating cell nuclear antigen expression during dopamine-triggered neuronal apoptosis. J. Neurochem. 69,539-549[Medline]
-
Nuydens, R., de Jong, M., Van Der Kieboom, G., Heers, C., Dispersyn, G., Conrelissen, F., Nuyens, R., Borgers, M., Geerts, H. (1998) Okadaic acid-induced apoptosis in neuronal cells: evidence for an abortive mitotic attempt. J. Neurochem. 70,1124-1133[Medline]
-
Bozyczko-Coine, D., McKenna, B. A., Siman, R. (1997) Caspase mediation of Aß neurotoxicity in vitro. Soc. Neurosci. Abstr. 23,633.9
-
Suzuki, A. (1997) Amyloid beta-protein induces necrotic cell death mediated by ICE cascade in PC12 cells. Exp. Cell Res. 234,507-511[Medline]
-
Arendt, T., Rodel, L., Gartner, U., Holzer, M. (1996) Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimers disease. NeuroReport 7,3047-3049[Medline]
-
Vincent, I., Rosado, M., Davies, P. (1996) Mitotic mechanisms in Alzheimers disease?. J. Cell Biol. 132,413-425[Abstract/Free Full Text]
-
McShea, A., Harris, P. L., Webster, K. R., Wahl, A. F., Smith, M. A. (1997) Abnormal expression of the cell cycle regulators p16 and cdk4 in Alzheimers disease. Am. J. Pathol. 150,1933-1939[Abstract]
-
Vincent, I., Jicha, G., Rosado, M., Dickson, D. W. (1997) Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimers disease brain. J. Neurosci. 17,3588-3598[Abstract/Free Full Text]
-
Busser, J., Geldmacher, D. S., Herrup, K. (1998) Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimers disease brain. J. Neurosci. 18,2801-2807[Abstract/Free Full Text]
-
Li, J., Xu, M., Zhou, H., Ma, J., Potter, H. (1997) Alzheimer presenilins in the nuclear membrane, interphase kinetochores, and centrosomes suggest a role in chromosome segregation. Cell 90,917-927[Medline]
-
Tamaru, T., Okada, M., Nakagawa, H. (1994) Differential expression of D type cyclins during neuronal maturation. Neurosci. Lett. 168,229-232[Medline]
This article has been cited by other articles:

|
 |

|
 |
 
J. Zhang, S. A. Cicero, L. Wang, R. R. Romito-DiGiacomo, Y. Yang, and K. Herrup
Nuclear localization of Cdk5 is a key determinant in the postmitotic state of neurons
PNAS,
June 24, 2008;
105(25):
8772 - 8777.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Amit, Y. Avramovich-Tirosh, M. B. H. Youdim, and S. Mandel
Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators
FASEB J,
May 1, 2008;
22(5):
1296 - 1305.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Simakova and N. J. Arispe
The Cell-Selective Neurotoxicity of the Alzheimer's A Peptide Is Determined by Surface Phosphatidylserine and Cytosolic ATP Levels. Membrane Binding Is Required for A Toxicity
J. Neurosci.,
December 12, 2007;
27(50):
13719 - 13729.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Copani, J. J. M. Hoozemans, F. Caraci, M. Calafiore, E. S. Van Haastert, R. Veerhuis, A. J. M. Rozemuller, E. Aronica, M. A. Sortino, and F. Nicoletti
DNA Polymerase-beta Is Expressed Early in Neurons of Alzheimer's Disease Brain and Is Loaded into DNA Replication Forks in Neurons Challenged with beta-Amyloid
J. Neurosci.,
October 25, 2006;
26(43):
10949 - 10957.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zhang, D. Qu, E. J. Morris, M. J. O'Hare, S. M. Callaghan, R. S. Slack, H. M. Geller, and D. S. Park
The Chk1/Cdc25A Pathway as Activators of the Cell Cycle in Neuronal Death Induced by Camptothecin.
J. Neurosci.,
August 23, 2006;
26(34):
8819 - 8828.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Bauer and P. H. Patterson
The cell cycle-apoptosis connection revisited in the adult brain
J. Cell Biol.,
November 21, 2005;
171(4):
641 - 650.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. O'Hare, N. Kushwaha, Y. Zhang, H. Aleyasin, S. M. Callaghan, R. S. Slack, P. R. Albert, I. Vincent, and D. S. Park
Differential Roles of Nuclear and Cytoplasmic Cyclin-Dependent Kinase 5 in Apoptotic and Excitotoxic Neuronal Death
J. Neurosci.,
September 28, 2005;
25(39):
8954 - 8966.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. C. Biswas, D. X. Liu, and L. A. Greene
Bim Is a Direct Target of a Neuronal E2F-Dependent Apoptotic Pathway
J. Neurosci.,
September 14, 2005;
25(37):
8349 - 8358.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Arcella, G. Carpinelli, G. Battaglia, M. D'Onofrio, F. Santoro, R. T. Ngomba, V. Bruno, P. Casolini, F. Giangaspero, and F. Nicoletti
Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo
Neuro-oncol,
July 1, 2005;
7(3):
236 - 245.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Hamdane, A. Bretteville, A.-V. Sambo, K. Schindowski, S. Begard, A. Delacourte, P. Bertrand, and L. Buee
p25/Cdk5-mediated retinoblastoma phosphorylation is an early event in neuronal cell death
J. Cell Sci.,
March 15, 2005;
118(6):
1291 - 1298.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Sortino, M. Chisari, S. Merlo, C. Vancheri, M. Caruso, F. Nicoletti, P. L. Canonico, and A. Copani
Glia Mediates the Neuroprotective Action of Estradiol on {beta}-Amyloid-Induced Neuronal Death
Endocrinology,
November 1, 2004;
145(11):
5080 - 5086.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Herrup, R. Neve, S. L. Ackerman, and A. Copani
Divide and Die: Cell Cycle Events as Triggers of Nerve Cell Death
J. Neurosci.,
October 20, 2004;
24(42):
9232 - 9239.
[Full Text]
|